Hidradenitis suppurativa and adalimumab in the COVID-19 era.
作者信息
Marzano Angelo Valerio, Moltrasio Chiara, Genovese Giovanni, Muratori Simona, Dapavo Paolo, Fabbrocini Gabriella, Patrizi Annalisa, Sechi Andrea, Micali Giuseppe, Pellegrino Michele, Gisondi Paolo, Dini Valentina, Bianchi Luca, Fania Luca, Offidani Annamaria, Prignano Francesca, Atzori Laura, Miraglia Emanuele, Cannavò Serafinella Patrizia, Bettoli Vincenzo, Stingeni Luca, Balestri Riccardo, Venturini Marina, Peris Ketty
机构信息
Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Department of Physiopathology and Transplantation, Università degli Studi di Milano, Milan, Italy.
Department of Physiopathology and Transplantation, Università degli Studi di Milano, Milan, Italy, Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy.
出版信息
Eur J Dermatol. 2020 Dec 1;30(6):748-749. doi: 10.1684/ejd.2020.3927.
Abstract
摘要
相似文献
1
Hidradenitis suppurativa and adalimumab in the COVID-19 era.新冠疫情时代的化脓性汗腺炎与阿达木单抗
Eur J Dermatol. 2020 Dec 1;30(6):748-749. doi: 10.1684/ejd.2020.3927.
2
Anti-COVID-19 measurements for hidradenitis suppurativa patients.防治化脓性汗腺炎患者感染 COVID-19 的措施。
Exp Dermatol. 2021 Jun;30 Suppl 1(Suppl 1):18-22. doi: 10.1111/exd.14339.
3
Is it worthy to treat hidradenitis suppurativa with adalimumab in patients with melanoma and other debilitating systemic diseases? A series of clinical dilemmas.对于患有黑色素瘤和其他使人衰弱的全身性疾病的患者，使用阿达木单抗治疗化脓性汗腺炎是否值得？一系列临床困境。
Australas J Dermatol. 2018 Nov;59(4):e297-e298. doi: 10.1111/ajd.12829. Epub 2018 Apr 19.
4
Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.阿达木单抗治疗伴发银屑病和化脓性汗腺炎有效：一组病例报告。
Indian J Dermatol Venereol Leprol. 2021 Mar-Apr;87(2):223-226. doi: 10.4103/ijdvl.IJDVL_455_18.
5
Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab.阿达木单抗和优特克单抗联合治疗克罗恩病合并化脓性汗腺炎取得成功。
Dermatol Online J. 2019 Sep 15;25(9):13030/qt0hw2w4nr.
6
Biologic therapy: a boon for hidradenitis suppurativa-like lesions complicating naevus comedonicus in a prepubertal child.生物疗法：治疗一名青春期前儿童黑头粉刺痣并发化脓性汗腺炎样皮损的福音。
Clin Exp Dermatol. 2019 Apr;44(3):322-324. doi: 10.1111/ced.13685. Epub 2018 Jun 11.
7
Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.阿达木单抗治疗与克罗恩病相关的化脓性汗腺炎。
Acta Dermatovenerol Croat. 2014;22(4):291-3.
8
Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials.阿达木单抗可缓解中度至重度化脓性汗腺炎患者的皮肤疼痛：PIONEER I和PIONEER II随机对照试验的次要疗效结果。
J Am Acad Dermatol. 2018 Dec;79(6):1141-1143. doi: 10.1016/j.jaad.2018.05.015. Epub 2018 May 19.
9
Clinical experience of the use of adalimumab in the management of hidradenitis suppurativa. Comparison of response rates with Crohn disease.阿达木单抗用于治疗化脓性汗腺炎的临床经验。与克罗恩病的缓解率比较。
Actas Dermosifiliogr. 2016 Sep;107 Suppl 2:43-50. doi: 10.1016/S0001-7310(17)30008-X.
10
Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic.COVID-19大流行期间肿瘤坏死因子-α抑制剂治疗化脓性汗腺炎的影响
J Cutan Med Surg. 2021 Jul-Aug;25(4):446-448. doi: 10.1177/1203475421997058. Epub 2021 Feb 24.
引用本文的文献
1
Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic.新冠疫情期间接受生物制剂治疗的银屑病和化脓性汗腺炎患者的皮肤表现
J Clin Med. 2021 Dec 13;10(24):5841. doi: 10.3390/jcm10245841.
2
Low incidence of COVID-19 in hidradenitis suppurativa: How to interpret it?化脓性汗腺炎中新冠病毒感染的低发病率：该如何解读？
Exp Dermatol. 2022 Mar;31(3):435-436. doi: 10.1111/exd.14475. Epub 2021 Nov 3.
3
Clinical Dermatology and COVID-19 Pandemic: Narrative Review.临床皮肤病学与新冠疫情：叙述性综述
Indian J Dermatol. 2021 May-Jun;66(3):246-255. doi: 10.4103/ijd.ijd_463_21.
4
Anti-COVID-19 measurements for hidradenitis suppurativa patients.防治化脓性汗腺炎患者感染 COVID-19 的措施。
Exp Dermatol. 2021 Jun;30 Suppl 1(Suppl 1):18-22. doi: 10.1111/exd.14339.
5
How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group.如何管理免疫介导的炎症性疾病中的新冠疫苗接种：免疫介导的炎症性疾病研究组的专家意见
Front Immunol. 2021 Apr 15;12:656362. doi: 10.3389/fimmu.2021.656362. eCollection 2021.
本文引用的文献
1
Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy.新冠疫情时代针对化脓性汗腺炎患者的生物制剂：来自意大利南部一家转诊中心的数据。
J Dermatolog Treat. 2022 Feb;33(1):592. doi: 10.1080/09546634.2020.1769828. Epub 2020 May 25.
2
Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations.阿达木单抗在2019冠状病毒病大流行期间用于治疗化脓性汗腺炎：安全性考量
J Am Acad Dermatol. 2020 Jul;83(1):e31. doi: 10.1016/j.jaad.2020.04.030. Epub 2020 Apr 10.
3
Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.管理 COVID-19 大流行期间的皮肤免疫介导性疾病。
Am J Clin Dermatol. 2020 Jun;21(3):307-311. doi: 10.1007/s40257-020-00514-2.
4
Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.阿达木单抗治疗化脓性汗腺炎“机会窗”的证据：一项回顾性、真实世界多中心队列研究。
Br J Dermatol. 2021 Jan;184(1):133-140. doi: 10.1111/bjd.18983. Epub 2020 Apr 13.
5
Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.国际化脓性汗腺炎严重程度评分系统（IHS4）的制定与验证，一种新型动态评分系统，用于评估 HS 严重程度。
Br J Dermatol. 2017 Nov;177(5):1401-1409. doi: 10.1111/bjd.15748. Epub 2017 Oct 30.
6
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.阿达木单抗治疗化脓性汗腺炎的两项 3 期临床试验。
N Engl J Med. 2016 Aug 4;375(5):422-34. doi: 10.1056/NEJMoa1504370.
Zotero 插件